Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment
Although Truveta Data is updated daily, we only used data through December 2024 as the last month of this analysis to allow for the 100-day prescription window
A 2018 review by Sikiric described its effects on the VEGF pathway, which drives the formation of new blood vessels (angiogenesis), and on the nitric oxide system, which regulates blood flow and inflammation
It thus constitutes a key tool for analyzing the quality of weight loss
US$ 23.13
US$ 26.16
US$ 23.63
US$ 27.98
US$ 29.51
US$ 25.17
